What Technical Indicators Show About VBI Vaccines Inc. (VBIV)?

0
48

VBI Vaccines Inc. (NASDAQ:VBIV) finished Wednesday with a subtraction of -$0.01 to close at $0.38, a downside of -2.67 percent. An average of 838,080 shares of common stock have been traded in the last five days. There was a fall of -$0.0632 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 1,114,125 shares traded, while the 50-day average volume stands at 899,264.

VBIV stock has decreased by -37.25% in the last month. The company shares reached their 1-month lowest point of $0.3710 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.38 and a high of $2.47 in 52 weeks. It has reached a new high 1 time so far this year and lost -83.93% or -$1.9640 in price. In spite of this, the price is down -84.78% from the 52-week high.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Valuation Metrics

VBI Vaccines Inc. (VBIV) stock’s beta is 1.71. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 105.20, the price-to-book (PB) ratio at 1.17.

Financial Health

The quick ratio of VBI Vaccines Inc. for the three months ended September 29 was 2.60, and the current ratio was 2.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.58 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at -$10.14 million compared to revenue of $0.63 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, VBI Vaccines Inc.’s return on assets was -59.30%.

Earnings Surprise

For the three-month period that ended September 29, VBI Vaccines Inc. had $48.42 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$25.21 million in the quarter, while revenues of -$45.7 million were grew 37.13%. The analyst consensus anticipated VBI Vaccines Inc.’s latest quarter earnings to come in at -$0.08 per share, but it turned out to be -$0.09, a -12.50% surprise. For the quarter, EBITDA amounted to -$20.62 million. Shareholders own equity worth $258.26 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at VBI Vaccines Inc. (VBIV) price momentum. RSI 9-day as of the close on 28 December was 23.55%, suggesting the stock is oversold, with historical volatility in this time frame at 63.10%.

As of today, VBIV’s price is $0.4012 -14.39% or -$0.0632 from its 5-day moving average. VBIV is currently trading -32.60% lower than its 20-day SMA and -64.53% lower than its 100-day SMA. However, the stock’s current price level is -44.21% below the SMA50 and -70.39% below the SMA200.

The stochastic %K and %D were 5.90% and 9.05%, respectively, and the average true range (ATR) was 0.0400. With the 14-day stochastic at 2.48% and the average true range at 0.0440, the RSI (14) stands at 27.18%. The stock has reached -0.0327 on the 9-day MACD Oscillator while the 14-day reading was at -0.0646.

Analyst Ratings

Raymond James downgraded VBI Vaccines Inc. (NASDAQ: VBIV) to a an Outperform rating in its most recent analyst report. Previously, the stock was rated as a Strong buy. The consensus rating for VBI Vaccines Inc. (VBIV) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell VBIV, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 1 others rate it as a “buy”.

What is VBIV’s price target for the next 12 months?

Analysts predict a range of price targets between $2.00 and $6.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for VBI Vaccines Inc. (VBIV) stock is $4.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here